Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Dow
Baxter
Medtronic
AstraZeneca
Moodys

Last Updated: June 27, 2022

Investigational Drug Information for Hetrombopag


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for Hetrombopag?

Hetrombopag is an investigational drug.

There have been 24 clinical trials for Hetrombopag. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2022.

The most common disease conditions in clinical trials are Thrombocytopenia, Anemia, Aplastic, and Purpura, Thrombocytopenic, Idiopathic. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Peking Union Medical College Hospital, and Yin Jie.

There are three US patents protecting this investigational drug and forty international patents.

Recent Clinical Trials for Hetrombopag
TitleSponsorPhase
Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective´╝îOpen-label, Single-arm Study.Tongji HospitalPhase 2
A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast CancerJiangsu HengRui Medicine Co., Ltd.Phase 2
A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast CancerHenan Cancer HospitalPhase 2

See all Hetrombopag clinical trials

Clinical Trial Summary for Hetrombopag

Top disease conditions for Hetrombopag
Top clinical trial sponsors for Hetrombopag

See all Hetrombopag clinical trials

US Patents for Hetrombopag

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Hetrombopag See Plans and Pricing Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof Jiangsu Hengrui Medicine Co. Ltd. (Jiangsu, CN) Shanghai Hengrui Pharmaceutical Co. Ltd. (Shanghai, CN) See Plans and Pricing
Hetrombopag See Plans and Pricing Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof Jiangsu Hengrui Medicine Co., Ltd. (CN) Shanghai Hengrui Pharmaceutical Co., Ltd. (CN) See Plans and Pricing
Hetrombopag See Plans and Pricing Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof Jiangsu Hengrui Medicine Co., Ltd. (CN) Shanghai Hengrui Pharmaceutical Co., Ltd. (CN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Hetrombopag

Drugname Country Document Number Estimated Expiration Related US Patent
Hetrombopag Australia AU2009207966 2028-01-10 See Plans and Pricing
Hetrombopag Brazil BRPI0907234 2028-01-10 See Plans and Pricing
Hetrombopag Canada CA2711535 2028-01-10 See Plans and Pricing
Hetrombopag China CN101481352 2028-01-10 See Plans and Pricing
Hetrombopag China CN101679286 2028-01-10 See Plans and Pricing
Hetrombopag European Patent Office EP2236500 2028-01-10 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Baxter
Medtronic
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.